New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Inhibrx Biosciences, Inc. (INBX) vs Jade Biosciences, Inc. (JBIO)

Inhibrx Biosciences, Inc. and Jade Biosciences, Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Jade Biosciences, Inc. are of similar size ($1.1B and $1.0B). Across the 8 metrics below, Inhibrx Biosciences, Inc. leads on 4 and Jade Biosciences, Inc. on 4.

Valuation

Metric INBX JBIO Biotechnology median
P/E n/m n/m 8.49
P/S 309.73 — 8.56
P/B n/m 2.41 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 331.80 — 8.00
Earnings yield (13.14%) (15.09%) (35.81%)
Free cash flow yield (12.24%) (11.87%) (25.41%)

Profitability

Metric INBX JBIO Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity 577.65% (49.75%) (51.58%)
Return on assets (71.23%) (45.85%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INBX JBIO Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) (108.03%) 78.57% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric INBX JBIO Biotechnology median
Debt to equity (3.22) 0.00 0.00
Current ratio 7.58 16.03 4.79
Net debt to EBITDA 0.18 2.94 1.01

Dividend

Metric INBX JBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INBX JBIO Biotechnology median
Market cap 1.10b 1.04b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack